AIMS: Novel bone turnover markers could help with the diagnosis and monitoring of osteomyelitis patients. We compared levels of two bone turnover markers, serum amino-terminal telopeptides (NTx) and bone alkaline phosphatase (BAP), in diabetic patients with and without osteomyelitis. METHODS: Matched case-control study was conducted with diabetic patients with and without osteomyelitis. Cases not undergoing immediate amputation were followed with repeat measurements after osteomyelitis treatment and for outcome determination. RESULTS: Analysis included 54 subjects, 27 cases and 27 controls. Median BAP levels were similar between cases and controls at enrollment (p=.55) as were median NTx levels (p=.43). Cases with follow-up data (n=18) had similar bone marker levels at enrollment and 6 weeks. No significant differences in BAP or NTx levels at enrollment or follow-up were seen between cases with poor versus favorable outcomes. CONCLUSIONS: No differences in NTx or BAP levels were seen between cases and controls. Cases with follow-up data had similar levels at enrollment and 6 weeks. Lack of difference may be due to small sample size, small areas of bone involved in foot osteomyelitis, or limitations of these specific markers. More research is needed.
AIMS: Novel bone turnover markers could help with the diagnosis and monitoring of osteomyelitispatients. We compared levels of two bone turnover markers, serum amino-terminal telopeptides (NTx) and bone alkaline phosphatase (BAP), in diabeticpatients with and without osteomyelitis. METHODS: Matched case-control study was conducted with diabeticpatients with and without osteomyelitis. Cases not undergoing immediate amputation were followed with repeat measurements after osteomyelitis treatment and for outcome determination. RESULTS: Analysis included 54 subjects, 27 cases and 27 controls. Median BAP levels were similar between cases and controls at enrollment (p=.55) as were median NTx levels (p=.43). Cases with follow-up data (n=18) had similar bone marker levels at enrollment and 6 weeks. No significant differences in BAP or NTx levels at enrollment or follow-up were seen between cases with poor versus favorable outcomes. CONCLUSIONS: No differences in NTx or BAP levels were seen between cases and controls. Cases with follow-up data had similar levels at enrollment and 6 weeks. Lack of difference may be due to small sample size, small areas of bone involved in foot osteomyelitis, or limitations of these specific markers. More research is needed.
Authors: Rayyan A Kayal; Dimitris Tsatsas; Megan A Bauer; Brian Allen; Maisa O Al-Sebaei; Sanjeev Kakar; Cataldo W Leone; Elise F Morgan; Louis C Gerstenfeld; Thomas A Einhorn; Dana T Graves Journal: J Bone Miner Res Date: 2007-04 Impact factor: 6.741
Authors: P Pennisi; S S Signorelli; S Riccobene; G Celotta; L Di Pino; T La Malfa; C E Fiore Journal: Osteoporos Int Date: 2003-12-06 Impact factor: 4.507